Hanmi Pharm. Co., Ltd. (KRX:128940)

Market Cap	3.03T
Revenue (ttm)	1.50T
Net Income (ttm)	121.32B
Shares Out	12.68M
EPS (ttm)	9,566.83
PE Ratio	24.98
Forward PE	20.85
Dividend	500.00 (0.21%)
Ex-Dividend Date	Dec 27, 2024

Volume	33,324
Average Volume	42,708
Open	239,500
Previous Close	239,000
Day's Range	233,000 - 239,500
52-Week Range	214,500 - 375,000
Beta	0.59
RSI	50.32
Earnings Date	Apr 30, 2025

About Hanmi Pharm.

Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company’s products include Gugutams, a urological combination therapy combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), and tadalafil, a treatment for erectile dysfunction (ED). The company ha...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1973
• Employees: 2,330
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 128940

Financial Performance

In 2024, Hanmi Pharm.'s revenue was 1.50 trillion, an increase of 0.31% compared to the previous year's 1.49 trillion. Earnings were 121.32 billion, a decrease of -17.04%.